In 2026, the global pharmaceutical packaging industry is facing major regulatory changes.
China's revised Regulations for the Implementation of the Drug Administration Law have officially taken effect, the United States has entered full enforcement of unit-level drug traceability under DSCSA, and the EU Pharma Package reform proposal has moved into the legislative stage.
As pharmaceutical packaging regulations continue to evolve, compliance has become closely linked to market access. This article provides an in-depth interpretation of these pivotal regulatory shifts.
China's revised regulations shift primary accountability from manufacturers to Marketing Authorization Holders (MAHs). Under the new framework, MAHs bear full legal responsibility for a drug's entire lifecycle, from raw material sourcing through distribution and post-market surveillance.
Every stage of the packaging process, including procurement of packaging materials, incoming inspection, line usage, and change control, must be documented in a manner that is fully traceable, tamper-evident, and auditable.
Gaps in data integrity are no longer just operational risks; they represent direct regulatory liability for the MAH.
Pharmaceutical companies must therefore establish robust lifecycle management systems for packaging materials.
The practical focus should be on building end-to-end data chains that can withstand regulatory scrutiny and clearly assign accountability at each node.
Following a decade of phased implementation, the DSCSA has transitioned into a period of full enforcement with no further exemptions.
As manufacturers and wholesale distributors met their respective compliance deadlines in May and August 2025, unit-level serialization has become a definitive benchmark for U.S. market access.
Today, high-speed coding and seamless data integration are no longer optional enhancements; they are baseline regulatory requirements. Packaging lines lacking these capabilities face the immediate risk of being excluded from the U.S. pharmaceutical supply chain.
Under FDA 21 CFR Part 211, all packaging equipment used in GMP production must complete Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) before commercial use, with all requirements documented in a Validation Master Plan (VMP). Requalification is mandatory after any significant modification.
Manufacturers planning to enter or expand their footprint in the U.S. market must proactively evaluate two core capabilities.
First, the production side’s capacity for unit-level serialization and DSCSA data exchange; and second, the completeness of equipment-side IQ/OQ/PQ validation documentation.
A trilogue agreement on the EU Pharma Package was reached in December 2025, with the final text published and the legislation formally entering the parliamentary process in 2026. While certain technical specifications remain under development, the regulatory direction is clearly established across 2 areas.
The reform strengthens physical integrity requirements for pharmaceutical packaging, with the objective of reducing the risk of falsified medicines entering the supply chain. Manufacturers will need to validate that their packaging formats meet enhanced tamper-evidence criteria for EU market access.
The Pharma Package deepens alignment with the Falsified Medicines Directive (FMD), with refined requirements around coding precision and verification processes. For manufacturers already operating under FMD, this represents an incremental but meaningful tightening of existing obligations.
With over 20 years of experience, PHARMAPACK is committed to helping manufacturers strengthen compliance, improve supply chain transparency, and adapt to evolving global requirements.
PHARMAPACK’s track and trace systems for bottle and carton packaging lines are fully compatible with China’s MAH requirements and the EU FMD. By assigning a globally unique identifier to every salable unit, these systems maintain an unbroken data chain from production through distribution.
PHARMAPACK’s smart inspection packaging line uses AI vision technology for product quality inspection, learning from sample data to accurately check packaging integrity and tamper-evidence.
For serialization and track-and-trace, PHARMAPACK’s proprietary high-speed cameras and algorithms enable fast, precise identification. Automatic focus and sensitivity adjustment support product changeovers in about five minutes.
We provide complete IQ/OQ/PQ validation documentation packages prepared to FDA 21 CFR Part 211 and cGMP standards, covering Installation Qualification, Operational Qualification, and Performance Qualification in full. Comprehensive validation support is a prerequisite for entering regulated markets and a practical foundation for passing compliance audits and accelerating equipment commissioning timelines.
As global pharmaceutical packaging regulations continue to converge around higher standards of accountability, traceability, and patient safety, the right technology partner can make the difference between reactive compliance and strategic readiness.
With over 20 years of expertise, PHARMAPACK delivers proven pharmaceutical packaging solutions, helping manufacturers navigate regulatory complexity with confidence.
https://www.nmpa.gov.cn/xxgk/fgwj/flxzhfg/20260127172639127.html
https://www.eawlogistics.com/pharmaceutical-serialization-and-track-and-trace-ensuring-compliance-in-2025/
https://www.thefdagroup.com/blog/a-basic-guide-to-iq-oq-pq-in-fda-regulated-industries
https://www.crowell.com/en/insights/client-alerts/the-new-eu-pharma-package-eu-reaches-landmark-deal-on-pharma-package